1. Home
  2. SIEB vs KPTI Comparison

SIEB vs KPTI Comparison

Compare SIEB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Siebert Financial Corp.

SIEB

Siebert Financial Corp.

HOLD

Current Price

$3.79

Market Cap

115.6M

Sector

Finance

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.95

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIEB
KPTI
Founded
1886
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.6M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SIEB
KPTI
Price
$3.79
$6.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
23.4K
165.8K
Earning Date
11-12-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.18
N/A
Revenue
$90,289,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
$3.18
P/E Ratio
$21.39
N/A
Revenue Growth
8.32
N/A
52 Week Low
$2.08
$3.51
52 Week High
$5.77
$12.45

Technical Indicators

Market Signals
Indicator
SIEB
KPTI
Relative Strength Index (RSI) 72.02 66.79
Support Level $2.82 $5.70
Resistance Level $3.05 $6.05
Average True Range (ATR) 0.26 0.45
MACD 0.09 0.16
Stochastic Oscillator 90.57 75.69

Price Performance

Historical Comparison
SIEB
KPTI

About SIEB Siebert Financial Corp.

Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: